March 28, 2011 |
Should you be paid to part with a kidney? It's an unseemly question, but it's one that medical professionals have been grappling with as the waiting list for kidneys gets longer, supply of the organs stagnates and other solutions fall short. In 1999, just over 40,000 Americans were on the waiting list for a kidney, according to the Scientific Registry of Transplant Recipients, a record that's overseen by the government. By 2009, the list had grown to nearly 83,000 people, the National Kidney Foundation says.
August 16, 2010 |
It's a hot day at Camp David in Mammoth, and teenagers are absorbed in an invigorating soccer game. As the sun beats down, the boys peel off their shirts and continue tearing around. All have the same energy and determination for their team to score a goal, but half are distinguished by the plastic catheters taped to their bellies. Diagnosed with severe kidney failure, they require daily treatments to stay alive and active. The National Kidney Foundation has sponsored them for a week at the YMCA-run camp.
April 13, 2008
Medicine: An article in the April 6 Opinion section about financial conflicts tainting medical research stated that the American Society of Nephrology issues clinical-practice guidelines. It should have said the National Kidney Foundation.
February 17, 2008 |
For more than six years, Jessica Harder was a model kidney-transplant patient. She surfed, competed in swimming competitions, worked as a lifeguard and managed to graduate from high school before turning 16. But her donated kidney, which she received when she was 12, wasn't as tough as she was. It gave out 16 months ago for reasons Harder thinks are linked to a short-sighted government policy. Simply put, although Medicare -- which covers most people with end-state renal disease -- pays for a kidney transplant, it limits the amount of time it pays for the drugs needed to keep the transplanted kidney functioning.
December 6, 2006 |
Amgen Inc., the Thousand Oaks-based biotech behemoth, has been a shining star in the drug industry for more than two decades. Recently, it isn't burning so brightly. This morning, Congress begins hearings about cost and safety concerns around two of the company's top-selling drugs, Epogen and Aranesp, which are used to treat nearly 2 1/2 million dialysis and cancer patients with anemia in the U.S. each year.
April 23, 2004 |
Last fall, the National Kidney Foundation for the first time set treatment guidelines to prevent a complication from kidney failure that causes damage to bones. The guidelines were tough, and there was no drug on the market that would easily help a patient meet them. Five months later, the Food and Drug Administration gave Amgen Inc. the OK to sell cinacalcet, an $8-a-day pill its sells under the name Sensipar to people on kidney dialysis.